Select the option that best describes what you are looking for
Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.
Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.
Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.
Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.
Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.
Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.
Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.
Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.
Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.
Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.
Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.
Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.
Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.
Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.
Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.
Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.
Certified CRO services with NanoString GeoMx Digital Spatial Profiling.
De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.
Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.
Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.
Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.
Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.
Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.
Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.
Learn more about how our consulting services can help to support your journey to the clinic.
Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.
Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.
We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.
We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.
Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.
Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.
Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.
Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.
Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.
Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.
With many new agents under development, including targeted therapies for gastric cancer, there is a need for predictive research models such as patient-derived xenografts (PDX) for preclinical evaluation. PDX models are proven to be highly predictive models for preclinical drug assessment. The Crown Bioscience collection contains over 100 well characterized gastric cancer PDX models, including EGFR amplified models and cachexic models. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER | CANCER TYPE | CANCER SUBTYPE | DESCRIPTION | # per page |
---|---|---|---|---|
GA0006 | Gastric Cancer | ADC | Adenocarcinoma of gastric cardia of lesser curvature side, ulcerative type, carcinoma in situ, moderately-poorly differentiated, tumor mass: 6.5cm x 5cm x 2.5cm. | CLICK TO VIEW |
GA0019 | Gastric Cancer | ADC | Adenocarcinoma of gastic cardia, infiltrative ulcerative type, moderately differentiated, tumor mass: 5cm x 4.5cm x 2.5cm, infiltrating into adipose tissue external serosa and nerve plexus in gastric wall. Malignant cells were observed in lesser curvature LN and cardial LN. | CLICK TO VIEW |
GA0022 | Gastric Cancer | ADC | Adenocarcinoma of gastic cardia, ulcerative type, moderately-poorly differentiated, tumor mass: 5cm x 4cm x 2.5cm, infiltrating gastric wall to serosa. No visible malignant cells adjacent to both stump. Regional LN: left gastric LN (5/9), LN of inferior parapulmonary vein (0/6). | CLICK TO VIEW |
GA0023 | Gastric Cancer | ADC | Adenocarcinoma, ulcerative type, poorly differenciated. | CLICK TO VIEW |
GA0025 | Gastric Cancer | Signet-ring cell carcinoma | Signet-ring cell carcinoma of gastric greater curvature, parts are mucinous adenocarcinoma, protruded type, tumor mass: 3.5cm x 3.5cm x 2cm, infiltrating into gastric wall. Regional LN: LN surround celiac trunk (1/1). IHC results: HER-1(-), HER-2(-), p53(-), p170(-), Ki-67(+ 25~50%), VEGF(+), TopIIa(+<25%), p16(-). | CLICK TO VIEW |
GA0031 | Gastric Cancer | ADC | Adenocarcinoma of stomach, ulcerative type, moderately-poorly differentiated, tumor mass: 6cm x 4cm x 1cm, infiltrating into serosa. No visible malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (2/5), LN of greater curvature (0/2). | CLICK TO VIEW |
GA0033 | Gastric Cancer | ADC | Adenocarcinoma of gastric cardia, ulcerative type, poorly differentiated, tumor mass: 9cm x 6cm x 1.5cm, infiltrating into serosa, and accompanied with necrosis and a few lymphocytes deposition. No visible malignant cells adjacent to both stump. Regional LN: cardial LN (0/5), left gastric LN (0/7). | CLICK TO VIEW |
GA0037 | Gastric Cancer | ADC | Adenocarcinoma of gastric cardia, ulcerative type,poorly differentiated, tumor mass: 4cm x 4cm x 2.5cm, infiltrating into serosa. No visible malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (0/9). | CLICK TO VIEW |
GA0044 | Gastric Cancer | ADC | Metastatic adenocarcinoma derived from liver, moderately-poorly differenciated. The patient had been done gastric cancer surgery 2 years ago. | CLICK TO VIEW |
GA0046 | Gastric Cancer | ADC | Adenocarcinoma derived from juncture of stomach and esophagus in lesser gastric curvature, protrude, ulcerative type, poorly differentiated, tumor mass: 6cm x 5cm x 1.5cm. Malignant cells infiltrating into gastric wall and esophagus. Regional LN: LN of lesser curvature (3/14). IHC results: HER-1(+), HER-2(-), p53(+ 25~50%), p170(-),Ki-67(+, 25-50%), VEGF(++), Top-IIa(+ about 10%), p16(-). | CLICK TO VIEW |
GA0055 | Gastric Cancer | ADC | Clear cell adenocarcinoma of anterior wall of gastric antrum, ulcerative type, moderately differentiated. Regional LN: LN of lesser curvature (2/6), LN of greater curvature (2/6), LN of the eighth group (1/1). IHC results: HER-1(-), HER-2(+), p53(+ 25~50%), p170(focus +), Ki-67(+<10%), VEGF(++), Top-IIa(+<1%), p16(++). | CLICK TO VIEW |
GA0060 | Gastric Cancer | ADC | Adenocarcinoma of gastric antrum, ulcerative type, moderately-poorly differentiated, tumor mass: 4cm x 6cm x 2cm, invaded adipose tissue external serosa, no visible malignant cells adjacent to both stump. Regional LN: LN of greater curvature (7/7), LN of lesser curvature (6/6). | CLICK TO VIEW |
GA0074 | Gastric Cancer | ADC | Adenocarcinoma of gastric cardia, ulcerative type, poorly differentiated, tumor mass: 5cm x 4cm x 0.8cm, invading deep muscular layer and massive gastric wall. No malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (1/3), cardial LN (0/5). | CLICK TO VIEW |
GA0075 | Gastric Cancer | ADC | Adenocarcinoma of cardia and fundus of stomach, infiltrative ulcerative type, moderately-poorly differentiated, tumor mass: 6.5cm x 5cm x 1.5cm, infiltrating into serosa. No malignant cells adjacent to both stump. Regional LN: LN of lesser curvature(1/6), cardial LN(0/4), LN of greater curvature (0/4), LN of para-inferior pulmonary vein (0/3). | CLICK TO VIEW |
GA0080 | Gastric Cancer | ADC | 1. Adenocarcinoma of gastric cardia, invasive type, moderately-poorly differentiated, tumor mass: 8cm x 6cm x 1.5cm, infiltrating into serosa. No visible malignant cells adjacent to both stump. Regional LN: cardial LN (1/5), left gastric LN (2/2). 2. Hepatitis, type B | CLICK TO VIEW |
GA0087 | Gastric Cancer | NEC, carcinoid | Carcinoid of gastric cardia, ulcerative type, tumor mass: 7cm x 5.5cm x 1.5cm, invading into serosa, no malignant cells adjacent to both stump and omentum majus. Regional LN: LN of lesser curvature (3/4), inferior esophageal LN (0/1). IHC results: Syn(-), CgA(+), NSE(-). | CLICK TO VIEW |
GA0091 | Gastric Cancer | NEC, carcinoid | Carcinoid of gastric cardia, ulcerative type, tumor mass: 7cm x 5.5cm x 1.5cm, invading into serosa, no malignant cells adjacent to both stump and omentum majus. Regional LN: LN of lesser curvature (3/4), inferior esophageal LN (0/1). IHC results: Syn(-), CgA(+), NSE(-). | CLICK TO VIEW |
GA0095 | Gastric Cancer | ADC | Adenocarcinoma of gastic cardia, ulcerative type, poorly differentiated, tumor mass: 6cm x 5cm x 2.5cm, invaded nerve plexus of gastric wall and adipose tissue external serosa. No visible malignant cells adjacent to superior stump. Severe acinar hyperplasia in inferior stump. Regional LN: lymphatic fusion were observed in lesser curvature and cardia. Metastatic tumor cell presented in the LN. | CLICK TO VIEW |
GA0098 | Gastric Cancer | ADC | Adenocarcinoma of gastric cardia, invasive, ulcerative type, moderately differentiated, tumor mass: 5cm x 4.5cm x 2cm, infiltrating into serosa and squamous epithelium of inferior esophagus. No visible malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/1), cardial LN (0/5). Lymphatic fusion were observed in lesser curvature. Metastatic tumor cell presented in the LN. | CLICK TO VIEW |
GA0103 | Gastric Cancer | ADC | moderately-poorly differentiated adenocarcinoma of gastric cardia (ulcerative) | CLICK TO VIEW |
GA0114 | Gastric Cancer | ADC | Gastric adenocarcinoma cancer patient-derived xenograft (PDX) model GA0114. | CLICK TO VIEW |
GA0119 | Gastric Cancer | ADC, mucinous | Adenocarcinoma of gastric cardia with mucinous adenocarcinoma and some signet-ring cell carcinoma, ulcerative type,poorly differentiated, tumor mass: 6.5cm x 7cm x 2cm, infiltrating into serosa and nerve plexus. Malignant cells adjacent to inferior stump. Regional LN: LN of lesser curvature (6/6), left gastric LN (5/6), inferior pyloric LN (1/1). | CLICK TO VIEW |
GA0138 | Gastric Cancer | ADC | Adenocarcinoma of stomach, invasive, ulcerative type, poorly differentiated, tumor mass: 11cm x 9cm x 3cm, infiltrating into deep muscular layer, no visible malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (1/5). | CLICK TO VIEW |
GA0139 | Gastric Cancer | ADC | Adenocarcinoma of gastric cardia with papillary adenocarcinoma, ulcerative type, moderately differentiated, tumor mass: 6.5cm x 7cm x 1cm, infiltrating into adipose tissue external serosa. No malignant cells adjacent to both stump. Regional LN: LN of lesser curvature (0/11), paraesophageal LN (0/4). | CLICK TO VIEW |
GA0151 | Gastric Cancer | ADC | Adenocarcinoma of gastric antrum, ulcerative type, moderately-poorly differentiated, tumor mass: 3cm x 2.5cm x 1cm, infiltrating into serosa. No visible malignant cells adjacent to both stump and omentum majus. Regional LN: LN of lesser curvature (1/4). | CLICK TO VIEW |
GA0152 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA0318 | Gastric Cancer | ADC | Adenocarcinoma of duodenal papilla. Infiltrating into pancreas. No visible malignant cells adjacent to both of stump and choledochal stump. Regional LN: LN of the twelfth group (0/1) | CLICK TO VIEW |
GA0429 | Gastric Cancer | ADC | Metastatic tubular adenocarcinoma in brain, consider originate from gastrointestinal tract.IHC results: CK(++), CEA(+), CK8/18(++), Ki67(++), CK7(+/-), PCNA(++), CK18(++), CK20(+), EMA(+). | CLICK TO VIEW |
GA1224 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of gastric cardia with hepatic metastases. The neoplastic cells are cubical and polygon cells with nuclear atypia. The tumor forms tubular and nest structures and has an infiltrative growth pattern. Regional LN: LN of lesser curvature (3/12), LN of greater curvature (0/4). | CLICK TO VIEW |
GA13732 | Gastric Cancer | NA | Gastroesophageal Carcinoma | CLICK TO VIEW |
GA13739 | Gastric Cancer | NA | NA | CLICK TO VIEW |
GA13741 | Gastric Cancer | ADC | N/A | CLICK TO VIEW |
GA13744 | Gastric Cancer | NA | Metastatic Gastric Carcinoma | CLICK TO VIEW |
GA13748 | Gastric Cancer | NA | Gastric Cancer | CLICK TO VIEW |
GA13750 | Gastric Cancer | N/A | N/A | CLICK TO VIEW |
GA13756 | Gastric Cancer | NA | Gastic Carcinoma | CLICK TO VIEW |
GA13760 | Gastric Cancer | NA | Gastric Carcinoma | CLICK TO VIEW |
GA13761 | Gastric Cancer | NA | Gastric Cancer | CLICK TO VIEW |
GA13762 | Gastric Cancer | NA | Stomach Carcinoma, KRUKENBERG TUMOR | CLICK TO VIEW |
GA13765 | Gastric Cancer | NA | Stomach Carcinoma | CLICK TO VIEW |
GA13766 | Gastric Cancer | NA | Stomach Carcinoma, adenocarcinoma of stomach. | CLICK TO VIEW |
GA13775 | Gastric Cancer | NA | NA | CLICK TO VIEW |
GA13777 | Gastric Cancer | ADC | Stomach Carcinoma. Adenocarcinoma. | CLICK TO VIEW |
GA13782 | Gastric Cancer | NA | Gastro-esophageal carcinoma, signet ring cell adenocarcinoma. | CLICK TO VIEW |
GA13801 | Gastric Cancer | ADC | N/A | CLICK TO VIEW |
GA13804 | Gastric Cancer | NA | Gastric ring cancer | CLICK TO VIEW |
GA13806 | Gastric Cancer | ADC | N/A | CLICK TO VIEW |
GA2101 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma of gastric antrum, in lesser curvature, ulcerative type, tumor mass: 3 x 3cm. The tumor invade through gastric wall. Caner embolus may be seen in vessel. Regional LN: NO.1 (black) LN (0/2), NO.1 LN (0/2), NO.3 LN (black) (0/5), NO.3 LN (1/1), NO.4SB LN (0/0), NO.4sd LN (0/1), NO.5 LN (0/2), NO.6 LN (0/4), NO.8 LN (0/8), NO.12A (0/2), NO.14V (0/0). IHC results: CD34(blood vessel +), CD44(focal +), cMet(-), D2-40(vessel +), EGFR(-), HER2(1+), Ki-67(+50~75%), MMP7(+), P170(+), P27(+<25%), P53(-), TOPOII(+<5%). | CLICK TO VIEW |
GA2103 | Gastric Cancer | ADC | Adenocarcinoma of gastric cardia with mucinous adenocarcinoma, ulcerative type, moderately differentiated, tumor mass: 8cm x 7cm, infiltrating through gastric wall. No malignant cells adjacent to stump. Regional LN: left cardial LN (1/1), LN of lesser curvature (4/6), right cardial LN (0/4), inferior pyloric LN (0/5), common hepatic arterial LN (0/4). IHC results; CD44(+), Cmet(+), EGFR(-), HER2(-), Ki-67(+25-50%), MMP7(+), P170(+), P27(+50-75%), P53(+>75%), TOPOII(+25-50%) | CLICK TO VIEW |
GA2109 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma of juncture of stomach and esophagus, ulcerative type, tumor mass: 5.0 x 4.5cm. The tumor invade through gastric wall. Regional LN: LN of lesser curvature (0/12), LN of greater curvature (0/2), NO.7,8 LN (0/4). IHC results: CD44(+), cMet(+), EGFR(-), HER2(1+), Ki-67(+ 25%), MMP7(+), P170(+), P27(+ 25%), P53(-), TOPOII(+ 25%). | CLICK TO VIEW |
GA2117 | Gastric Cancer | ADC | Metastatic mucinous adenocarcinoma from tissue surrounding navel | CLICK TO VIEW |
GA2140 | Gastric Cancer | ADC | Gastric adenocarcinoma,poorly differentiated | CLICK TO VIEW |
GA2148 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of gastric antrum and lesser curvature, ulcerative type, tumor mass: 2.0 x 1.5cm. The tumor invade gastric serosa and nervus. Regional LN: NO.3 LN (1/4), NO.1 LN (0/1), NO.4D LN (0/2), NO.7 LN (0/5), NO.8 LN (0/6), NO.8P LN (0/5), NO.11P LN ( 0/2), NO.12 LN (0/1). IHC results: CD44(+), cMet(+), EGFR(+ 75%), HER2(-), Ki-67(+ 75%), MMP7(-), P170(-), P27(+ 75%), P53(+ 25%), TOPOII(+ 25%). | CLICK TO VIEW |
GA2157 | Gastric Cancer | ADC | Moderately-poorly differentiated adenocarcinoma of gastric antrum, with part of signet ring cell carcinoma, ulcerative type, tumor mass: 5.0 x 5.0cm. The tumor invade through gastric wall to serosa of pancreas and gallbladder. Regional LN: NO.1 LN (6/8), NO.3 LN (14/17), NO.5 LN (2/2), NO.6 LN (2/2), NO.7 LN (4/6), NO.4D LN (10/11), NO.8 LN (1/2). IHC results: CD44(+), cMet(weak +), EGFR(+), HER2(3+), Ki-67(+50-75%), MMP7(-), P170(-), P27(+50-75%), P53(+>75%), TOPOII(-). | CLICK TO VIEW |
GA2180 | Gastric Cancer | NA | NA | CLICK TO VIEW |
GA2192 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of gastric cardia and fundus, ulcerative type. The tumor invade through gastric wall. | CLICK TO VIEW |
GA2228 | Gastric Cancer | SCC | N/A | CLICK TO VIEW |
GA2253 | Gastric Cancer | Adenocarcinoma | NA | CLICK TO VIEW |
GA2254 | Gastric Cancer | ADC and Signet-ring cell carcinoma | Moderately to poorly differentiated adenocarcinoma with signet ring cell carcinoma | CLICK TO VIEW |
GA2256 | Gastric Cancer | N/A | N/A | CLICK TO VIEW |
GA2257 | Gastric Cancer | NA | Ovarian: signet-ring cell carcinoma and poorly differentiated adenocarcinoma, considered gastric cancer on basis of medical history. | CLICK TO VIEW |
GA2269 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma of antrum of stomach, tumor size: 5.5x5cm, infiltrating through gastric wall. Six of sixteen lymph nodes involved by metastatic carcinoma. | CLICK TO VIEW |
GA2278 | Gastric Cancer | ADC | No dianosis info from hospital. | CLICK TO VIEW |
GA2315 | Gastric Cancer | Mucinous adenocarcinoma | NA | CLICK TO VIEW |
GA2419 | Gastric Cancer | ADC | NA for clinical diagnosis info. | CLICK TO VIEW |
GA2420 | Gastric Cancer | ADC | NA for clinical diagnosis info. | CLICK TO VIEW |
GA2421 | Gastric Cancer | ADC | NA for clinical diagnosis info. | CLICK TO VIEW |
GA2434 | Gastric Cancer | ADC | NA for clinical diagnosis info. | CLICK TO VIEW |
GA2435 | Gastric Cancer | ADC | NA for clinical diagnosis info. | CLICK TO VIEW |
GA3049 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma of gastric antrum. The tumor forms irregular glandular or cribriform structures and has an infiltrative growth pattern. Regional LN: LN of proximal lesser curvature (0/9), LN of distal lesser curvature (0/7), LN of proximal greater curvature (1/3), LN of distal greater curvature (4/7), common hepatic arterial LN (1/1). | CLICK TO VIEW |
GA3055 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma of stomach | CLICK TO VIEW |
GA3102 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of stomach with hepatic metastases. Regional LN: LN of proximal lesser curvature (17/18), LN of distal lesser curvature (9/9), porta hepatic LN (1/1), LN of proximal greater curvature (0/8), LN of distal greater curvature (0/3), mesenteric LN (0/1). | CLICK TO VIEW |
GA3109 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma of gastric antrum. The tumor forms irregular glandular or cribriform structures and has an infiltrative growth pattern. Regional LN: LN of proximal lesser curvature (0/9), LN of distal lesser curvature (0/7), LN of proximal greater curvature (1/3), LN of distal greater curvature (4/7), common hepatic arterial LN (1/1). | CLICK TO VIEW |
GA3121 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma from juncture of stomach and esophagus. | CLICK TO VIEW |
GA3155 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma of stomach. The tumor forms glandular or cribriform structures and has an infiltrative growth pattern. Regional LN: LN of proximal greater curvature (0/2), LN of distal greater curvature (0/5), LN of proximal lesser curvature (5/8), LN of distal lesser curvature (3/7). | CLICK TO VIEW |
GA3158 | Gastric Cancer | ADC, mucinous | Mucinous adenocarcinoma, infiltrating through gastric wall and duodenal wall . Twenty-four of forty-one lymph nodes involved by metastatic carcinoma (24/41). IHC results: TS(-), b-tubulin(100%+~++), Ki67TP(-), ERCC-1(-), cMet(-), TopoIIa(20%++), CerbB2(-). | CLICK TO VIEW |
GA3236 | Gastric Cancer | ADC | Poorly to moderately differentiated adenocarcinoma of antrum of stomach, infiltrating to submucosa. Seven of seventeen lymph nodes involved by metastatic carcinoma (7/17). | CLICK TO VIEW |
GA3341 | Gastric Cancer | ADC | Residual stomach: poorly differentiated adenocarcinoma, infiltrating to serosa. Six of sixteen lymph nodes involved by metastatic carcinoma (6/16). | CLICK TO VIEW |
GA6200 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of stomach, infiltrating to serosa. All lymph nodes are benign (0/15) | CLICK TO VIEW |
GA6201 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of gastric lesser curvature, infiltrating subserosa. Four of twenty lymph nodes involved by metastatic carcinoma (4/20). | CLICK TO VIEW |
GA6202 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of stomach, infiltrating subserosa. Two of thirty lymph nodes involved by metastatic carcinoma (2/30). | CLICK TO VIEW |
GA6203 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of gastric body, infiltrating out of serosa. Four of sixteen lymph nodes involved by metastatic carcinoma (4/16). | CLICK TO VIEW |
GA6207 | Gastric Cancer | N/A | N/A | CLICK TO VIEW |
GA6208 | Gastric Cancer | ADC | Tubular adenocarcinoma of stomach, grade II-III, infiltrating to subserosa. Two of thirteen lymph nodes involved by metastatic carcinoma. | CLICK TO VIEW |
GA6209 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of stomach, infiltrating to serosa. One out of six lymph nodes showed metastatic adenocarcinoma (1/6). | CLICK TO VIEW |
GA6210 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of gastric lesser curvature, infiltrating to serosa. All lymph nodes are benign (0/21). | CLICK TO VIEW |
GA6211 | Gastric Cancer | ADC | Moderately differentiated tubular adenocarcinoma. Tumor invaded to subserosal liver. Fourteen of thirty-two lymph nodes involved by metastatic carcinoma(14/32). | CLICK TO VIEW |
GA6212 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma of pylorus, infiltrating to serosa. All lymph nodes are benign (0/52). | CLICK TO VIEW |
GA6214 | Gastric Cancer | ADC | Tubular adenocarcinoma of fundus of stomach, grade II-III. Tumor invaded to serosa, all lymph nodes are benign (0/24). | CLICK TO VIEW |
GA6215 | Gastric Cancer | ADC | Adenocarcinoma of stomach, grade II. Tumor cells show glandular structure, atypia and invade to subserosal fibrofatty tissue. Five of twenty-two lymph nodes involved by metastatic carcinoma. | CLICK TO VIEW |
GA6239 | Gastric Cancer | ADC | Gastric angle: mucinous adenocarcinoma, poorly differentiated, infiltrating to serosa. Twenty-one out of thirty-one lymph nodes showed metastatic adenocarcinoma (21/31). | CLICK TO VIEW |
GA6240 | Gastric Cancer | N/A | N/A | CLICK TO VIEW |
GA6273 | Gastric Cancer | ADC | Antrum of stomach: poorly differentiated adenocarcinoma. Eight of thirty-two lymph nodes involved by malignant carcinoma (8/32) | CLICK TO VIEW |
GA6275 | Gastric Cancer | ADC | Lesser curvature side of stomach: tubular adenocarcinoma, grade II, with mucinous component, infiltrating to serosa. All lymph nodes are benign (0/19). | CLICK TO VIEW |
GA6276 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma of stomach, infiltrating to subserosal fibrous tissue. All lymph nodes are benign (0/23). | CLICK TO VIEW |
GA6305 | Gastric Cancer | ADC | Lesser curvature of stomach: poorly differentiated adenocarcinoma, with mucinous adenocarcinoma component | CLICK TO VIEW |
GA6806 | Gastric Cancer | NA | Gastric adenocarcinoma. | CLICK TO VIEW |
GA6807 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma, HER2 (2+) | CLICK TO VIEW |
GA6810 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma, HER2(2+) | CLICK TO VIEW |
GA6811 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma | CLICK TO VIEW |
GA6812 | Gastric Cancer | NA | NA | CLICK TO VIEW |
GA6815 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6816 | Gastric Cancer | NA | NA | CLICK TO VIEW |
GA6819 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma, HER2(-) | CLICK TO VIEW |
GA6820 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma. HER2 (2+) | CLICK TO VIEW |
GA6821 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma. HER2 (2+) | CLICK TO VIEW |
GA6822 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma. HER2 (2+) | CLICK TO VIEW |
GA6823 | Gastric Cancer | N/A | N/A | CLICK TO VIEW |
GA6825 | Gastric Cancer | Adenocarcinoma | NA | CLICK TO VIEW |
GA6828 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6829 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6830 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma | CLICK TO VIEW |
GA6831 | Gastric Cancer | ADC | Intramucosal adenocarcinoma | CLICK TO VIEW |
GA6832 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma | CLICK TO VIEW |
GA6833 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6834 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6836 | Gastric Cancer | ADC | Well differentiated adenocarcinoma | CLICK TO VIEW |
GA6839 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6843 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6844 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6846 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma | CLICK TO VIEW |
GA6864 | Gastric Cancer | NA | NA for clinical diagnosis info. | CLICK TO VIEW |
GA6865 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma of fundus to antrum of stomach, infiltrating through gastric wall. sixteen of thirty-four lymph nodes involved by metastatic carcinoma (16/34). | CLICK TO VIEW |
GA6866 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma, ulcerative type, infiltrating to serosa. IHC: CD44(+),Cmet(+),EGFR(-),HER2(1+),Ki-67(+25-50%), MMP7(-), P170(+), P27(-), P53(+>75%), TOPOII(+25-50%). | CLICK TO VIEW |
GA6869 | Gastric Cancer | ADC | Gastric-esophageal junction: poorly differentiated adenocarcinoma, infiltrating to gastric serosa. 32 of 42 lymph nodes involved by metastatic carcinoma (32/42). | CLICK TO VIEW |
GA6871 | Gastric Cancer | ADC | gastric adenocarcinoma, poorly differentiated | CLICK TO VIEW |
GA6873 | Gastric Cancer | ADC | Gastric-esophageal junction: poorly differentiated adenocarcinoma, infiltrating through gastric wall. 4 of 39 lymph nodes involved by metastatic carcinoma (4/39). | CLICK TO VIEW |
GA6875 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of antrum of stomach, infiltrating to deep muscularis. No lymph nodes involved by metastatic carcinoma (0/19). | CLICK TO VIEW |
GA6876 | Gastric Cancer | ADC | Gastric cardia: poorly differentiated adenocarcinoma, infiltrating through gastric wall. 10 of 14 lymph nodes involved by metastatic carcinoma (10/14). | CLICK TO VIEW |
GA6877 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma of antrum of stomach, infiltrating through gastric wall. No lymph nodes involved by metastatic carcinoma (0/39). | CLICK TO VIEW |
GA6878 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma of antrum of stomach, infiltrating through gastric wall. Two of sixty lymph nodes involved by metastatic carcinoma (2/60). | CLICK TO VIEW |
GA6881 | Gastric Cancer | ADC | Moderately differentiated adenocarcinoma from juncture of stomach and esophagus, infiltrating through gastric wall. No lymph nodes involved by metastatic carcinoma (0/18). | CLICK TO VIEW |
GA6882 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma from juncture of stomach and esophagus, infiltrating through gastric wall to esophagus. Ten of thirty-six lymph nodes involved by metastatic carcinoma (10/36). | CLICK TO VIEW |
GA6885 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of antrum of stomach, infiltrating through gastric wall. One of twenty-one lymph nodes involved by metastatic carcinoma (1/21). | CLICK TO VIEW |
GA6889 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of antrum of stomach, infiltrating to serosa. One of twenty-six lymph nodes involved by metastatic carcinoma (1/26). | CLICK TO VIEW |
GA6891 | Gastric Cancer | ADC | Moderately to poorly differentiated adenocarcinoma of antrum of stomach, infiltrating through gastric wall. One of five lymph nodes involved by metastatic carcinoma (1/5). | CLICK TO VIEW |
GA6894 | Gastric Cancer | ADC | Poorly differentiated adenocarcinoma of antrum of stomach (Lauren typing: mixed type), infiltrating through gastric wall. Two of thirty lymph nodes involved by metastatic carcinoma (2/30). | CLICK TO VIEW |
GA6897 | Gastric Cancer | ADC | Lesser curvature of stomach: poorly differentiated adenocarcinoma, infiltrating through gastric wall. | CLICK TO VIEW |
GA6898 | Gastric Cancer | NA | NA for clinical diagnosis info. | CLICK TO VIEW |
Already Registered? Login
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy